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Author	(year)	 Study	type	 Population	 Primary	route	of	T	treatment	 Primary	outcome	 Ref.	
	 	 	 	 	 	
Patch	 	 	 	 	 	Braunstein	(2005)	 RCT	 447	SM	on	E	 TTP	24	weeks	150/300/450μg	doses	 Increased	sexual	activity	and	desire	(PFSF)	in	300ug	dose	 41	Buster	(2005)	 RCT	 533	SM	on	E	 TTP	24	weeks	 Increased	sexual	activity	and	desire	(PFSF),	reduced	distress	 42	Davis	(2006)	 RCT	 77	SM	on	E	 TTP	24	weeks	 Improved	sexual	desire	on	PFSF	 38	Davis	(2008)	 RCT	 814	NM	and	SM,	not	on	HT	 TTP	24	weeks	150/300μg	doses	 Increased	sexual	activity	and	desire	(PFSF),	reduced	distress	for	300μg	dose	 43	Davis	(2009)	 Retrospective	cohort	 631	PM	women	 Transdermal	or	implant	 No	increased	risk	breast	cancer.	RR	1.35	(95%	CI	0.76-2.38)	 86	Davis	(2009b)	 RCT	 279,	no	HT	 TTP	24	weeks	150/300μg	doses	 No	effect	on	mammographic	density	 89	Fooladi	(2014)	 RCT	 44	pre	and	PM	women	with	SSRI/SNRI-emergent	loss	of	libido	 TTP	12	weeks	 Increased	satisfactory	sexual	events	 56	Hofling	(2007a+b)	 RCT	 99	PM	on	CEE/NET	 TTP	24	weeks	 Reduction	in	breast	cell	proliferation,	no	effect	on	mammographic	density	 87,	88	Iellamo	(2010)	 RCT	 36	older	PM	with	heart	failure	 TTP	24	weeks	 Improved	functional	capacity,	insulin	resistance	and	muscle	strength	 213	Panay	(2010)	 RCT	 272	NM,	mainly	not	on	HT	 TTP	24	weeks	 Increased	sexual	activity	and	desire	(PFSF),	reduced	distress	 55	
	 52	
Popat	(2014)	 RCT	 145	POI	 TTP	12	weeks	150μg	 No	additional	benefit	from	T	at	12	weeks	but	projected	benefit	at	3	years	using	repeated	measures	model	 71	Shifren	(2000)	 RCT	 75	SM	on	CE	 TTP	12	weeks	150/300μg	doses	 Increased	sexual	activity	and	pleasure-orgasm	and	psychological	well-being	 54	Shifren	(2006)	 RCT	 549	NM	on	HT	 TTP	24	weeks	 Increased	sexual	activity	and	desire	(PFSF),	reduced	distress	 39	Simon	(2005)	 RCT	 562	SM	on	E	 TTP	24	weeks	 Increased	sexual	activity	(x2	episodes/wk)	and	desire	(PFSF),	reduced	distress	 40	Vitale	(2008)	 Pooled	analysis	on	5	RCTs	 2795	NM	and	SM,	with	and	without	HT	 TTP	24-52	weeks	 No	effect	on	CV	events	or	risk	factors	(lipids,	insulin,	glucose,	BP),	except	reduction	in	HDL	increases)	 192		 	 	 	 	 	
Gel/cream	 	 	 	 	 	Davis	(2014)	 RCT	 92	PM	women,	no	HT	 Transdermal	gel,	300ug	daily	26	weeks	 Improved	verbal	learning	and	memory	 66	Gruber	(1998)	 RCT	 39	NM	women	not	on	HT	 Transdermal	gel,	24	weeks	 Reduction	in	BMI,	total	body	weight	and	abdominal	fat	 179	Nathorst-Boos	(2006)	 RCT,	cross	over	 53	PM	on	HT	 Transdermal	gel,	10mg	daily,	24	weeks	 Increased	sexual	activity,	desire,	orgasm	and	arousal.	Improved	psychological	well-being.	 57	Shah	(2006)	 RCT	 76	PM	on	E	 Transdermal	gel,	400muL	daily	16	weeks	 Improved	immediate	and	delayed	visual	and	verbal	memory,	unaffected	by	AI	 65		 	 	 	 	 	
	 53	
White	(2012)	 RCT	 3-4000	 Transdermal	gel,	0.22g/d,	>12	months	 Composite	of	CV	events	-	results	not	yet	reported.	 193	Witherby	(2011)	 Open	label	pilot	 21	PM	women	with	BC	and	AI	induced	vaginal	atrophy	 Vaginal	cream	300/150μg	doses	daily	for	4	weeks	 Improvement	on	dyspareunia,	dryness,	vaginal	pH	and	maturation	index	with	300ug	dose	 59	
	 	 	 	 	 	







































































































































































		 Mean	difference	in	B-PFSF		 95%	CI	 p	
HSDD	
(n=14)	 5.36	 1.9-8.8	 <0.05	
No	HSDD	













Mean	difference	 95%	CI	 	 p	value	
FSH	(U/L)	 9.60	 	 -1.1	to	20.3	 0.077	
Estradiol	(pmol/L)	 -89.4	 	 -245.0	to	67.2	 0.349	
SHBG	(nmol/L)	 -5.50	 	 -16.5	to	5.5	 0.099	
Total	Testosterone	(nmol/L)	 1.26	 	 0.8	to	1.7	 <0.0001	












Mean	difference	 95%	CI	 	 p	value	
		 	 	 	 	 	
Weight	 0.443	 	 -0.18	to	1.07	 0.211	
BMI	 -0.159	 	 -0.38	to	0.07	 0.218	
Waist	Circumference	(cm)	 -0.262	 	 -1.38	to	0.86	 0.661	
Hip	Circumference	(cm)	 -0.738	 	 -1.42	to	-0.05	 <0.05	
Systolic	BP	 -2.52	 	 -7.02	to	1.98	 0.265	
Diastolic	BP	 1.81	 	 -2.80	to	6.42	 0.342	
Fasting	Glucose	(mmol/L)	 0.053	 	 -0.12	to	0.23	 0.533	
Fasting	Insulin	(pmol/L)	 5.809	 	 -10.66	to	22.27	 0.5	
HOMA-IR	 0.106	 	 -0.20	to	0.41	 0.705	
Total	cholesterol	(nmol/L)	 -0.0053	 	 -0.24	to	0.23	 0.964	
HDL	cholesterol	(mmol/L)	 -0.251	 	 -0.51	to	0.0071	 <0.05	
Total	chol:HDL	 -0.776	 	 -0.54	to	0.38	 0.689	
Lipoprotein	(a)	(mg/L)	 -3.11	 	 -76.32	to	13.75	 <0.05	
Bilirubin	(umol/L)	 -0.714	 	 -3.56	to	2.13	 0.888	












Table	12.	Summary	of	results	obtained	from	radial	artery	applanation	tonometry			 Baseline	 3	months	 Change	 95%	CI	 p	
AIx	 23.30	 24.37	 1.067	 -3.85	to	1.72	 0.433	
EFI	 14.43	 25.74	 11.31	 -3.18	to	25.79	 0.62	
∆	AIx	salbutamol	 -2.90	 -5.07	 2.167	 -0.49	to	4.83	 <0.05	












(n=16)	and	>5	years	(n=5).		 	 			 Mean	difference	 	 95%	CI	 	p	
AIx	 -3.02	 	 -9.49	-	3.44	 0.339	
EFI	 20.47	 	 -12.50	-	53.44	 0.209	





		 E+P	(n=16)	 E	only	(n=5)	 			 Mean	difference	 95%	CI	 p	 Mean	difference	 95%	CI	 p	 Between	group	p	
		 	 	 	 	 	 	 	B-PFSF	 6.19	 3.34	to	9.04	 <0.0005	 1.4	 -2.87	to	5.67	 0.414	 0.077	
Total	chol	 0.157	 -0.83	to	1.14	 0.736	 -0.04	 -0.77	to	0.69	 0.887	 0.862	
HDL	 -0.06	 0.51	to	0.38	 0.777	 -0.134	 -0.4	to	0.13	 0.232	 0.693	
Lipo	(a)	 -5.071	 -38.28	to	28.14	 0.747	 4.18	 -7.38	to	15.74	 0.372	 <0.05	
HOMA-IR	 0.193	 -0.33	to	0.72	 0.4404	 -0.1	 -0.45	to	0.25	 0.473	 0.398	
	 	 	 	 	 	 	 	AIx	 -0.06	 -3.4	to	3.3	 0.973	 4.63	 -0.2	to	9.5	 0.06	 0.129	
EFI	 17.53	 0.99	to	34.1	 <0.05	 -7.36	 -43.4	to	28.7	 0.6	 0.123	
RHI	 0.02	 -0.3	to	0.3	 0.916	 -0.19	 -0.6	to	0.2	 0.258	 0.557	
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